Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Syros Pharmaceuticals, Inc. (SYRS)
USD0.00
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
35 CambridgePark Drive 2140
Cambridge, MA, US
Cambridge, MA, US
CEO
James E. Bradner
Website
syros.com
IPO
2016-06-30
CIK 1556263 ISIN US87184Q2066
Description
Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia. SY-2101: An innovative oral formulation of arsenic trioxide, intended for the treatment of acute promyelocytic leukemia. SY-5609: A cyclin-dependent kinase 7 inhibitor, which is being assessed in a Phase I clinical study involving patients with specific advanced solid tumors. Syros maintains several strategic alliances, notably a research collaboration and option agreement with Incyte Corporation centered on identifying therapeutic targets for myeloproliferative neoplasms. Furthermore, the company has a licensing arrangement with TMRC Co. Ltd. pertaining to the development and commercialization of tamibarotene. Initially incorporated in 2011 as LS22, Inc., the company officially adopted the name Syros Pharmaceuticals, Inc. in August 2012. Its corporate headquarters are located in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Tyme | TYME | 2022-07-18 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11.4K
Beta
1.27
Float Shares
26.82M
Free Float %
99.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -50.00% | +0.00% | -60.00% | -42.86% | -99.48% | -99.99% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Hold
Price Targets & DCF
Current price
0.00
Low
5.00
+4,999,900.0%
Consensus
16.67
+16,669,900.0%
Median
15.00
+14,999,900.0%
High
30.00
+29,999,900.0%
Ratings Trend (MoM)
0% Bullish
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 4 |
15.75
+15,749,900.0%
|
Quality scores
Altman Z-Score
-15.54
Distress
Piotroski F-Score
0 / 9
Weak
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-33.2% Q3'24: -100.0% (vs Q3'23)
-
EPS growth Biotechnology: +29.7%+22.4% Q3'24: +88.8% (vs Q3'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,585.5%
-
EBIT margin Biotechnology: +0.0%-1,604.7%
-
ROIC Biotechnology: -16.1%— Q3'24: +221.7% (vs Q3'23)
-
Share dilution Biotechnology: -3.4%+124.2% Q3'24: +40.5% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.39× Q3'24: -3.16× (vs Q3'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.10M
est: 1.10M (+0.0%)
|
2.05M
est: 1.56M (+31.3%)
|
1.98M
est: 2.16M (-8.1%)
|
15.09M
est: 12.11M (+24.6%)
|
23.49M
est: 20.48M (+14.7%)
|
14.88M
est: 19.47M (-23.6%)
|
9.94M
est: 4.15M (+139.5%)
|
450.0K
est.
|
5.00M
est.
|
1.67M
1.67M – 1.67M
-66.7% YoY
|
1.67M
1.67M – 1.67M
+0.0% YoY
|
1.67M
1.67M – 1.67M
+0.0% YoY
|
31.87M
31.87M – 31.87M
+1,811.9% YoY
|
| EBITDA |
-53.16M
est: -1.10M (-4,730.4%)
|
-60.68M
est: -1.56M (-3,785.5%)
|
-72.72M
est: -2.16M (-3,270.7%)
|
-79.21M
est: -12.11M (-554.0%)
|
-79.63M
est: -20.48M (-288.7%)
|
-87.55M
est: -19.47M (-349.8%)
|
-157.20M
est: -4.15M (-3,688.7%)
|
-450.0K
est.
|
-5.00M
est.
|
-1.67M
-1.67M – -1.67M
+66.7% YoY
|
-1.67M
-1.67M – -1.67M
+0.0% YoY
|
-1.67M
-1.67M – -1.67M
+0.0% YoY
|
-31.87M
-31.87M – -31.87M
-1,811.9% YoY
|
| EBIT |
-54.69M
est: -1.10M (-4,869.2%)
|
-62.28M
est: -1.56M (-3,888.2%)
|
-75.44M
est: -2.16M (-3,396.9%)
|
-82.25M
est: -12.11M (-579.1%)
|
-82.65M
est: -20.48M (-303.5%)
|
-90.52M
est: -19.47M (-365.0%)
|
-159.45M
est: -4.15M (-3,743.0%)
|
-450.0K
est.
|
-5.00M
est.
|
-1.67M
-1.67M – -1.67M
+66.7% YoY
|
-1.67M
-1.67M – -1.67M
+0.0% YoY
|
-1.67M
-1.67M – -1.67M
+0.0% YoY
|
-31.87M
-31.87M – -31.87M
-1,811.9% YoY
|
| Net Income |
-54.01M
est: -599.09M (+91.0%)
|
-62.28M
est: -527.26M (+88.2%)
|
-75.44M
est: -523.22M (+85.6%)
|
-84.04M
est: -481.18M (+82.5%)
|
-86.56M
est: -425.29M (+79.6%)
|
-94.65M
est: -265.32M (+64.3%)
|
-164.57M
est: -109.77M (-49.9%)
|
-42.47M
est.
|
-26.92M
est.
|
-17.10M
-17.10M – -17.10M
+36.5% YoY
|
-18.28M
-18.28M – -18.28M
-6.9% YoY
|
-18.49M
-18.49M – -18.49M
-1.2% YoY
|
-19.86M
-19.86M – -19.86M
-7.4% YoY
|
| SGA |
13.89M
est: 3.97M (+249.7%)
|
16.16M
est: 5.64M (+186.8%)
|
21.48M
est: 7.79M (+175.9%)
|
21.33M
est: 43.71M (-51.2%)
|
23.04M
est: 73.93M (-68.8%)
|
29.30M
est: 70.26M (-58.3%)
|
28.28M
est: 14.97M (+88.9%)
|
1.62M
est.
|
18.05M
est.
|
6.02M
6.02M – 6.02M
-66.7% YoY
|
6.02M
6.02M – 6.02M
+0.0% YoY
|
6.02M
6.02M – 6.02M
+0.0% YoY
|
115.01M
115.01M – 115.01M
+1,811.9% YoY
|
| EPS |
-21.26
est: -21.15 (-0.5%)
|
-19.07
est: -18.61 (-2.4%)
|
-18.76
est: -18.47 (-1.6%)
|
-18.25
est: -16.99 (-7.4%)
|
-13.84
est: -15.01 (+7.8%)
|
-7.49
est: -9.37 (+20.0%)
|
-5.81
est: -3.88 (-49.9%)
|
-1.50
est.
|
-0.95
est.
|
-0.60
-0.60 – -0.60
+36.6% YoY
|
-0.65
-0.65 – -0.65
-6.9% YoY
|
-0.65
-0.65 – -0.65
-1.2% YoY
|
-0.70
-0.70 – -0.70
-7.4% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-107.63M
OE per share TTM
-2.80
Owner's Yield
-1,370,452.11%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
205.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
45
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Syros Pharmaceuticals, Inc. | 17.82M | 9.90% | — | 17.82M | — | 17.82M | CO | — | 2022-07-13 | ↗ |
| 2 | Tyme Technologies, Inc. | 17.46M | 28.00% | — | 17.46M | — | 11.00 | CO | — | 2022-07-13 | ↗ |
| 3 | ARK Investment Management LLC | 8.59M | 13.94% | 7.85M | 186.6K | 8.59M | — | IA | Delaware, United States | 2021-03-10 | ↗ |
| 4 | (“SMTH”) | 4.97M | 11.72% | — | 4.97M | — | 4.97M | FI, HC | Japan | 2020-02-12 | ↗ |
| 5 | Artal Group S.A. | 3.50M | 5.60% | 3.50M | — | 3.50M | — | OO | — | 2022-02-11 | ↗ |
| 6 | Artal International Management S.A. | 3.50M | 5.60% | 3.50M | — | 3.50M | — | OO | — | 2022-02-11 | ↗ |
| 7 | Artal International S.C.A. | 3.50M | 5.60% | 3.50M | — | 3.50M | — | OO | — | 2022-02-11 | ↗ |
| 8 | Invus Public Equities Advisors, LLC | 3.50M | 5.60% | 3.50M | — | 3.50M | — | OO | — | 2022-02-11 | ↗ |
| 9 | Invus Public Equities, L.P. | 3.50M | 5.60% | 3.50M | — | 3.50M | — | PN | — | 2022-02-11 | ↗ |
| 10 | Mr. Amaury Wittouck | 3.50M | 5.60% | 3.50M | — | 3.50M | — | IN | — | 2022-02-11 | ↗ |
| 11 | Stichting Administratiekantoor Westend | 3.50M | 5.60% | 3.50M | — | 3.50M | — | OO | — | 2022-02-11 | ↗ |
| 12 | Westend S.A. | 3.50M | 5.60% | 3.50M | — | 3.50M | — | OO | — | 2022-02-11 | ↗ |
| 13 | ABG Management Ltd. | 3.03M | 5.40% | — | 3.03M | — | 3.03M | CO | Cayman Islands | 2020-12-18 | ↗ |
| 14 | Ally Bridge Group (NY) LLC | 3.03M | 5.40% | — | 3.03M | — | 3.03M | OO | Cayman Islands | 2020-12-18 | ↗ |
| 15 | Ally Bridge MedAlpha Management GP, LLC | 3.03M | 5.40% | — | 3.03M | — | 3.03M | OO | Cayman Islands | 2020-12-18 | ↗ |
| 16 | Ally Bridge MedAlpha Management L.P. | 3.03M | 5.40% | — | 3.03M | — | 3.03M | PN | Cayman Islands | 2020-12-18 | ↗ |
| 17 | Ally Bridge MedAlpha Master Fund L.P. | 3.03M | 5.40% | — | 3.03M | — | 3.03M | PN | Cayman Islands | 2020-12-18 | ↗ |
| 18 | Fan Yu | 3.03M | 5.40% | — | 3.03M | — | 3.03M | IN | Cayman Islands | 2020-12-18 | ↗ |
| 19 | Avidity Capital Partners (GP) LLC | 2.12M | 9.90% | — | 2.12M | — | 2.12M | OO | Delaware | 2022-09-20 | ↗ |
| 20 | Avidity Capital Partners Fund (GP) LP | 2.12M | 9.90% | — | 2.12M | — | 2.12M | PN, OO | Delaware | 2022-09-20 | ↗ |
| 21 | Avidity Partners Management (GP) LLC | 2.12M | 9.90% | — | 2.12M | — | 2.12M | OO | Delaware | 2022-09-20 | ↗ |
| 22 | Avidity Partners Management LP | 2.12M | 9.90% | — | 2.12M | — | 2.12M | IA, PN | Delaware | 2022-09-20 | ↗ |
| 23 | David Witzke | 2.12M | 9.90% | — | 2.12M | — | 2.12M | IN | Delaware | 2022-09-20 | ↗ |
| 24 | Michael Gregory | 2.12M | 9.90% | — | 2.12M | — | 2.12M | IN | Delaware | 2022-09-20 | ↗ |
| 25 | Srinivas Akkaraju | 1.61M | 7.50% | 17.0K | 1.59M | 17.0K | 10.00 | IN | United States | 2023-10-20 | ↗ |
| 26 | Samsara BioCapital GP, LLC | 1.59M | 7.40% | — | 1.59M | — | 10.00 | OO | Delaware | 2023-10-20 | ↗ |
| 27 | Samsara BioCapital, L.P. | 1.59M | 7.40% | — | 1.59M | — | 10.00 | PN | Delaware | 2023-10-20 | ↗ |
| 28 | (1) BlackRock, Inc. | 1.52M | 2.40% | 1.52M | — | 1.52M | — | HC | Delaware | 2022-07-08 | ↗ |
| 29 | Blue Owl Capital Holdings LP | 1.49M | 5.74% | 1.49M | — | 1.49M | — | PN | Delaware | 2024-02-14 | ↗ |
| 30 | Point72 Asset Management, L.P. | 1.47M | 5.70% | — | 1.47M | — | — | PN | Delaware | 2024-01-02 | ↗ |
| 31 | Point72 Capital Advisors, Inc. | 1.47M | 5.70% | — | 1.47M | — | — | CO | Delaware | 2024-01-02 | ↗ |
| 32 | Steven A. Cohen | 1.47M | 5.70% | — | 1.47M | — | — | IN | Delaware | 2024-01-02 | ↗ |
| 33 | Adage Capital Advisors, L.L.C. | 1.25M | 6.04% | — | 1.25M | — | — | OO | Delaware | 2023-01-25 | ↗ |
| 34 | Adage Capital Partners GP, L.L.C. | 1.25M | 6.04% | — | 1.25M | — | — | OO | Delaware | 2023-01-25 | ↗ |
| 35 | Adage Capital Partners, L.P. | 1.25M | 6.04% | — | 1.25M | — | — | PN | Delaware | 2023-01-25 | ↗ |
| 36 | Phillip Gross | 1.25M | 6.04% | — | 1.25M | — | — | IN | United States | 2023-01-25 | ↗ |
| 37 | Robert Atchinson | 1.25M | 6.04% | — | 1.25M | — | — | IN | United States | 2023-01-25 | ↗ |
| 38 | Avidity Private Master Fund I LP | 1.17M | 5.60% | — | 1.17M | — | 1.17M | PN, OO | Delaware | 2022-09-20 | ↗ |
| 39 | David Kroin | 699.3K | 9.99% | — | 699.3K | — | — | HC, IN | United States | 2022-09-19 | ↗ |
| 40 | Deep Track Biotechnology Master Fund, Ltd. | 699.3K | 9.99% | — | 699.3K | — | — | CO | Cayman Islands | 2022-09-19 | ↗ |
| 41 | Deep Track Capital, LP | 699.3K | 9.99% | — | 699.3K | — | — | IA, OO | Delaware | 2022-09-19 | ↗ |
| 42 | Bain Capital Life Sciences Fund II, L.P. | 10.00 | 9.99% | — | 5.79M | — | 5.79M | PN | Cayman Islands | 2020-12-14 | ↗ |
| 43 | Nikko Asset Management Americas, Inc. | — | 0.00% | — | — | — | — | IA | USA | 2022-02-14 | ↗ |
| 44 | Nikko Asset Management Co., Ltd. (“NAM”) | — | 0.00% | — | — | — | — | FI, IA, HC | Japan | 2022-02-04 | ↗ |
| 45 | Sumitomo Mitsui Trust Holdings, Inc. (“SMTH”) | — | 0.00% | — | — | — | — | FI, HC | Japan | 2022-02-04 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ADVISOR GROUP HOLDINGS, INC. | — -113.0 (-100.0%) | — -24.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 13 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.31
Bearish
Ratio by volume
0.16
Bearish
Buys
5
Sells
16
Shares acquired
111.9K
Shares disposed
678.4K
Cash buys
—
Cash sales
7.00
Net activity
-566,483
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-02 | Simonian Nancy A | Director | S-Sale | D | Common Stock | 37,070 | 0.27 | 10.0K | 4,000 | D | ↗ |
| 2024-11-25 | Simonian Nancy A | Director | S-Sale | D | Common Stock | 134,713 | 0.27 | 35.7K | 41,070 | D | ↗ |
| 2024-11-19 | Quirk Gerald E | Officer | S-Sale | D | Common Stock | 46,657 | 0.22 | 10.3K | 0 | D | ↗ |
| 2024-11-18 | Stephens Kristin | Officer | S-Sale | D | Common Stock | 36,133 | 0.22 | 7.9K | 0 | D | ↗ |
| 2024-11-18 | Roth David | Officer | S-Sale | D | Common Stock | 12,099 | 0.20 | 2.4K | 0 | D | ↗ |
| 2024-11-18 | Haas Jason | Officer | S-Sale | D | Common Stock | 137,803 | 0.21 | 29.0K | 0 | D | ↗ |
| 2024-11-18 | Chee Conley | Director / Officer | S-Sale | D | Common Stock | 134,797 | 0.20 | 26.9K | 0 | D | ↗ |
| 2024-10-31 | Stephens Kristin | Officer | F-InKind | D | Common Stock | 6,104 | 2.09 | 12.8K | 36,133 | D | ↗ |
| 2024-10-31 | Simonian Nancy A | Director | M-Exempt | D | Restricted Stock Units | 40,125 | 0.00 | — | 0 | D | ↗ |
| 2024-10-31 | Roth David | Officer | F-InKind | D | Common Stock | 6,776 | 2.09 | 14.2K | 12,099 | D | ↗ |
| 2024-10-31 | Haas Jason | Officer | F-InKind | D | Common Stock | 5,624 | 2.09 | 11.8K | 137,803 | D | ↗ |
| 2024-10-31 | Chee Conley | Director / Officer | M-Exempt | D | Restricted Stock Units | 17,000 | 0.00 | — | 0 | D | ↗ |
| 2024-09-30 | Quirk Gerald E | Officer | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 49,757 | D | ↗ |
| 2024-09-16 | Young Richard A | Director | M-Exempt | D | Restricted Stock Units | 2,667 | 0.00 | — | 2,667 | — | ↗ |
| 2024-09-16 | AKKARAJU SRINIVAS | Director | M-Exempt | A | Common Stock | 2,667 | 0.00 | — | 9,333 | — | ↗ |
| 2024-09-12 | Haas Jason | Officer | P-Purchase | A | Common Stock | 45,344 | 1.68 | 76.0K | 124,552 | — | ↗ |
| 2024-09-11 | Haas Jason | Officer | P-Purchase | A | Common Stock | 19,293 | 1.58 | 30.4K | 79,208 | — | ↗ |
| 2024-09-11 | Chee Conley | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 1.71 | 85.4K | 122,504 | — | ↗ |
| 2024-09-10 | Haas Jason | Officer | P-Purchase | A | Common Stock | 35,363 | 1.55 | 54.8K | 59,915 | — | ↗ |
| 2024-09-10 | Chee Conley | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 1.51 | 75.3K | 72,504 | — | ↗ |
| 2024-06-28 | Young Richard A | Director | S-Sale | D | Common Stock | 34,837 | 5.12 | 178.4K | 8,000 | — | ↗ |
| 2024-06-05 | Young Richard A | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 5.30 | 31.8K | 6,000 | — | ↗ |
| 2024-06-05 | WIRTH PETER | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 16,000 | — | ↗ |
| 2024-06-05 | TYSON TIMOTHY | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 5.30 | 31.8K | 6,000 | — | ↗ |
| 2024-06-05 | Simonian Nancy A | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 5.30 | 31.8K | 6,000 | — | ↗ |
| 2024-06-05 | OH ANDREW M. | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 5.30 | 31.8K | 6,000 | — | ↗ |
| 2024-06-05 | Fanucci Marsha | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 5.30 | 31.8K | 6,000 | — | ↗ |
| 2024-06-05 | Eckhardt Sue Gail | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 16,000 | — | ↗ |
| 2024-06-05 | Dunsire Deborah | Director | A-Award | A | Restricted Stock Units | 4,000 | 0.00 | — | 4,000 | — | ↗ |
| 2024-06-05 | AKKARAJU SRINIVAS | Director | A-Award | A | Restricted Stock Units | 4,000 | 0.00 | — | 4,000 | — | ↗ |
| 2024-06-01 | Dunsire Deborah | Director | M-Exempt | A | Common Stock | 4,000 | 0.00 | — | 12,000 | — | ↗ |
| 2024-06-01 | AKKARAJU SRINIVAS | Director | M-Exempt | A | Common Stock | 4,000 | 0.00 | — | 6,666 | — | ↗ |
| 2024-04-03 | Roth David | Officer | S-Sale | D | Common Stock | 10,451 | 4.95 | 51.7K | 0 | — | ↗ |
| 2024-04-02 | Roth David | Officer | S-Sale | D | Common Stock | 150 | 4.98 | 747.05 | 10,451 | — | ↗ |
| 2024-04-01 | Stephens Kristin | Officer | F-InKind | D | Common Stock | 4,218 | 5.12 | 21.6K | 25,237 | — | ↗ |
| 2024-04-01 | Simonian Nancy A | Director | F-InKind | D | Common Stock | 14,052 | 5.12 | 71.9K | 131,658 | — | ↗ |
| 2024-04-01 | Roth David | Officer | F-InKind | D | Common Stock | 4,732 | 5.12 | 24.2K | 10,601 | — | ↗ |
| 2024-04-01 | Haas Jason | Officer | F-InKind | D | Common Stock | 4,732 | 5.12 | 24.2K | 24,552 | — | ↗ |
| 2024-04-01 | Chee Conley | Director / Officer | F-InKind | D | Common Stock | 3,500 | 5.12 | 17.9K | 22,504 | — | ↗ |
| 2024-03-31 | Stephens Kristin | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 4,000 | — | ↗ |
| 2024-03-31 | Simonian Nancy A | Director | M-Exempt | A | Common Stock | 39,566 | 0.00 | — | 145,710 | — | ↗ |
| 2024-03-31 | Roth David | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2024-03-31 | Haas Jason | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 4,000 | — | ↗ |
| 2024-03-31 | Chee Conley | Director / Officer | M-Exempt | A | Common Stock | 11,666 | 0.00 | — | 26,004 | — | ↗ |
| 2024-03-28 | Quirk Gerald E | Officer | F-InKind | D | Common Stock | 7,046 | 5.59 | 39.4K | 39,757 | — | ↗ |
| 2024-03-27 | Quirk Gerald E | Officer | M-Exempt | A | Common Stock | 22,500 | 0.00 | — | 46,803 | — | ↗ |
| 2023-12-21 | AKKARAJU SRINIVAS | Director | P-Purchase | A | Common Stock | 904,977 | 4.42 | 4.00M | 1,786,427 | — | ↗ |
| 2023-12-12 | Roth David | Officer | S-Sale | D | Common Stock | 6,287 | 4.95 | 31.1K | 0 | — | ↗ |
| 2023-12-06 | Roth David | Officer | S-Sale | D | Common Stock | 6,287 | 3.95 | 24.8K | 6,287 | — | ↗ |
| 2023-12-02 | Chee Conley | Director / Officer | A-Award | A | Restricted Stock Units | 86,000 | 0.00 | — | 86,000 | — | ↗ |
| 2023-12-01 | Simonian Nancy A | Director | D-Return | D | Stock Option (right to buy) | 17,499 | 109.00 | 1.91M | 0 | — | ↗ |
| 2023-11-01 | Stephens Kristin | Officer | F-InKind | D | Common Stock | 5,676 | 2.22 | 12.6K | 15,789 | — | ↗ |
| 2023-11-01 | Simonian Nancy A | Director / Officer | F-InKind | D | Common Stock | 13,401 | 2.22 | 29.8K | 100,144 | — | ↗ |
| 2023-11-01 | Roth David | Officer | F-InKind | D | Common Stock | 6,301 | 2.22 | 14.0K | 12,574 | — | ↗ |
| 2023-11-01 | Haas Jason | Officer | F-InKind | D | Common Stock | 6,301 | 2.22 | 14.0K | 13,951 | — | ↗ |
| 2023-11-01 | Chee Conley | Officer | F-InKind | D | Common Stock | 6,004 | 2.22 | 13.3K | 12,338 | — | ↗ |
| 2023-10-31 | Stephens Kristin | Officer | M-Exempt | D | Restricted Stock Units | 17,000 | 0.00 | — | 17,000 | — | ↗ |
| 2023-10-31 | Simonian Nancy A | Director / Officer | M-Exempt | D | Restricted Stock Units | 40,125 | 0.00 | — | 40,125 | — | ↗ |
| 2023-10-31 | Roth David | Officer | M-Exempt | A | Common Stock | 18,875 | 0.00 | — | 18,875 | — | ↗ |
| 2023-10-31 | Haas Jason | Officer | M-Exempt | A | Common Stock | 18,875 | 0.00 | — | 20,252 | — | ↗ |
| 2023-10-31 | Chee Conley | Officer | M-Exempt | D | Restricted Stock Units | 17,000 | 0.00 | — | 17,000 | — | ↗ |
| 2023-10-19 | Quirk Gerald E | Officer | F-InKind | D | Common Stock | 6,897 | 2.10 | 14.5K | 24,303 | — | ↗ |
| 2023-10-11 | Quirk Gerald E | Officer | M-Exempt | A | Common Stock | 22,500 | 0.00 | — | 31,200 | — | ↗ |
| 2023-09-16 | Young Richard A | Director | M-Exempt | D | Restricted Stock Units | 2,666 | 0.00 | — | 5,334 | — | ↗ |
| 2023-09-16 | Alles Mark J | Director | M-Exempt | D | Restricted Stock Units | 2,666 | 0.00 | — | 5,334 | — | ↗ |
| 2023-09-16 | AKKARAJU SRINIVAS | Director | M-Exempt | A | Common Stock | 2,666 | 0.00 | — | 2,666 | — | ↗ |
| 2023-09-12 | Quirk Gerald E | Officer | A-Award | A | Restricted Stock Units | 30,000 | 0.00 | — | 30,000 | — | ↗ |
| 2023-07-31 | Roth David | Officer | S-Sale | D | Common Stock | 7,348 | 3.95 | 29.0K | 0 | — | ↗ |
| 2023-07-17 | Olson Eric R | Officer | S-Sale | D | Common Stock | 689 | 3.50 | 2.4K | 6,661 | — | ↗ |
| 2023-06-01 | Young Richard A | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 3.70 | 22.2K | 6,000 | — | ↗ |
| 2023-06-01 | WIRTH PETER | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 3.70 | 22.2K | 6,000 | — | ↗ |
| 2023-06-01 | TYSON TIMOTHY | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 3.70 | 22.2K | 6,000 | — | ↗ |
| 2023-06-01 | OH ANDREW M. | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 3.70 | 22.2K | 6,000 | — | ↗ |
| 2023-06-01 | Fanucci Marsha | Director | A-Award | A | Common Stock | 4,000 | 0.00 | — | 12,000 | — | ↗ |
| 2023-06-01 | Eckhardt Sue Gail | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 3.70 | 22.2K | 6,000 | — | ↗ |
| 2023-06-01 | Dunsire Deborah | Director | A-Award | A | Restricted Stock Units | 4,000 | 0.00 | — | 4,000 | — | ↗ |
| 2023-06-01 | Alles Mark J | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 3.70 | 22.2K | 6,000 | — | ↗ |
| 2023-06-01 | AKKARAJU SRINIVAS | Director | A-Award | A | Restricted Stock Units | 4,000 | 0.00 | — | 4,000 | — | ↗ |
| 2023-04-03 | Stephens Kristin | Officer | F-InKind | D | Common Stock | 623 | 2.58 | 1.6K | 4,465 | — | ↗ |
| 2023-04-03 | Simonian Nancy A | Director / Officer | F-InKind | D | Common Stock | 1,852 | 2.58 | 4.8K | 73,420 | — | ↗ |
| 2023-04-03 | Roth David | Officer | F-InKind | D | Common Stock | 623 | 2.58 | 1.6K | 7,348 | — | ↗ |
| 2023-04-03 | Olson Eric R | Officer | F-InKind | D | Common Stock | 623 | 2.58 | 1.6K | 7,350 | — | ↗ |
| 2023-04-03 | Haas Jason | Officer | F-InKind | D | Common Stock | 623 | 2.58 | 1.6K | 1,377 | — | ↗ |
| 2023-04-03 | Chee Conley | Officer | F-InKind | D | Common Stock | 658 | 2.58 | 1.7K | 1,342 | — | ↗ |
| 2023-03-31 | Stephens Kristin | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 5,088 | — | ↗ |
| 2023-03-31 | Simonian Nancy A | Director / Officer | M-Exempt | A | Common Stock | 6,000 | 0.00 | — | 75,272 | — | ↗ |
| 2023-03-31 | Roth David | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 6,000 | — | ↗ |
| 2023-03-31 | Olson Eric R | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 7,973 | — | ↗ |
| 2023-03-31 | Haas Jason | Officer | M-Exempt | D | Restricted Stock Units | 2,000 | 0.00 | — | 6,000 | — | ↗ |
| 2023-03-31 | Chee Conley | Officer | M-Exempt | A | Common Stock | 2,000 | 0.00 | — | 2,000 | — | ↗ |
| 2023-02-16 | Stephens Kristin | Officer | A-Award | A | Restricted Stock Units | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-02-16 | Simonian Nancy A | Director / Officer | A-Award | A | Restricted Stock Units | 118,700 | 0.00 | — | 118,700 | — | ↗ |
| 2023-02-16 | Roth David | Officer | A-Award | A | Restricted Stock Units | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-02-16 | Olson Eric R | Officer | A-Award | A | Restricted Stock Units | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2023-02-16 | Haas Jason | Officer | A-Award | A | Restricted Stock Units | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2023-02-16 | Chee Conley | Officer | A-Award | A | Restricted Stock Units | 35,000 | 0.00 | — | 35,000 | — | ↗ |
| 2022-10-11 | Quirk Gerald E | Officer | A-Award | A | Restricted Stock Units | 45,000 | 0.00 | — | 45,000 | — | ↗ |
| 2022-10-06 | Stephens Kristin | Officer | A-Award | A | Restricted Stock Units | 34,000 | 0.00 | — | 34,000 | — | ↗ |
| 2022-10-06 | Simonian Nancy A | Officer | A-Award | A | Restricted Stock Units | 80,250 | 0.00 | — | 80,250 | — | ↗ |
| 2022-10-06 | Roth David | Officer | A-Award | A | Stock Option (right to buy) | 49,750 | 0.00 | — | 49,750 | — | ↗ |
| 2022-10-06 | Olson Eric R | Officer | A-Award | A | Restricted Stock Units | 34,000 | 0.00 | — | 34,000 | — | ↗ |
| 2022-10-06 | Haas Jason | Officer | A-Award | A | Stock Option (right to buy) | 49,750 | 0.00 | — | 49,750 | — | ↗ |
| 2022-10-06 | Chee Conley | Officer | A-Award | A | Stock Option (right to buy) | 44,500 | 0.00 | — | 44,500 | — | ↗ |
| 2022-09-29 | TYSON TIMOTHY | Director | P-Purchase | A | Common Stock | 14,000 | 6.37 | 89.2K | 24,932 | — | ↗ |
| 2022-09-16 | Young Richard A | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 7.35 | 88.2K | 12,000 | — | ↗ |
| 2022-09-16 | WIRTH PETER | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2022-09-16 | TYSON TIMOTHY | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-16 | OH ANDREW M. | Director | A-Award | A | Common Stock | 8,000 | 0.00 | — | 8,000 | — | ↗ |
| 2022-09-16 | Fanucci Marsha | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 7.35 | 88.2K | 12,000 | — | ↗ |
| 2022-09-16 | Eckhardt Sue Gail | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 7.35 | 88.2K | 12,000 | — | ↗ |
| 2022-09-16 | Dunsire Deborah | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 7.35 | 88.2K | 12,000 | — | ↗ |
| 2022-09-16 | Alles Mark J | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 7.35 | 88.2K | 12,000 | — | ↗ |
| 2022-09-16 | AKKARAJU SRINIVAS | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 7.35 | 88.2K | 12,000 | — | ↗ |
| 2022-06-01 | Young Richard A | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 0.78 | 13.7K | 17,500 | — | ↗ |
| 2022-06-01 | WIRTH PETER | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-06-01 | SHARP PHILLIP A | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-06-01 | Nashat Amir | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-06-01 | Fanucci Marsha | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-06-01 | Eckhardt Sue Gail | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-06-01 | Dunsire Deborah | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-06-01 | Alles Mark J | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-06-01 | AKKARAJU SRINIVAS | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 0.00 | — | 17,500 | — | ↗ |
| 2022-04-01 | Stephens Kristin | Officer | F-InKind | D | Common Stock | 14,115 | 1.12 | 15.8K | 30,885 | — | ↗ |
| 2022-04-01 | Simonian Nancy A | Officer | F-InKind | D | Common Stock | 58,883 | 1.12 | 65.9K | 692,723 | — | ↗ |
| 2022-04-01 | Roth David | Officer | F-InKind | D | Common Stock | 27,281 | 1.12 | 30.6K | 59,719 | — | ↗ |
| 2022-04-01 | Olson Eric R | Officer | F-InKind | D | Common Stock | 27,266 | 1.12 | 30.5K | 59,734 | — | ↗ |
| 2022-02-15 | Stephens Kristin | Officer | A-Award | A | Restricted Stock Units | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-02-15 | Simonian Nancy A | Director / Officer | A-Award | A | Stock Option (right to buy) | 375,000 | 1.59 | 596.3K | 375,000 | — | ↗ |
| 2022-02-15 | Roth David | Officer | A-Award | A | Restricted Stock Units | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-02-15 | Olson Eric R | Officer | A-Award | A | Restricted Stock Units | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-02-15 | Haas Jason | Officer | A-Award | A | Restricted Stock Units | 80,000 | 0.00 | — | 80,000 | — | ↗ |
| 2022-02-15 | Chee Conley | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 1.59 | 159.0K | 100,000 | — | ↗ |
| 2022-01-05 | Olson Eric R | Officer | S-Sale | D | Common Stock | 2,208 | 3.47 | 7.7K | 0 | — | ↗ |
| 2021-10-12 | Haas Jason | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-09-27 | Chee Conley | Officer | A-Award | A | Stock Option (right to buy) | 360,000 | 4.81 | 1.73M | 360,000 | — | ↗ |
| 2021-09-09 | Dunsire Deborah | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 5.28 | 184.8K | 35,000 | — | ↗ |
| 2021-07-01 | Olson Eric R | Officer | S-Sale | D | Common Stock | 1,164 | 5.55 | 6.5K | 0 | — | ↗ |
| 2021-06-08 | Young Richard A | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 6.30 | 110.3K | 17,500 | — | ↗ |
| 2021-06-08 | WIRTH PETER | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 6.30 | 110.3K | 17,500 | — | ↗ |
| 2021-06-08 | Stephens Kristin | Officer | — | D | Common Stock | 0 | 0.00 | — | 45,000 | — | ↗ |
| 2021-06-08 | SHARP PHILLIP A | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 6.30 | 110.3K | 17,500 | — | ↗ |
| 2021-06-08 | Nashat Amir | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 6.30 | 110.3K | 17,500 | — | ↗ |
| 2021-06-08 | Fanucci Marsha | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 6.30 | 110.3K | 17,500 | — | ↗ |
| 2021-06-08 | Eckhardt Sue Gail | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 6.30 | 110.3K | 17,500 | — | ↗ |
| 2021-06-08 | Alles Mark J | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 6.30 | 110.3K | 17,500 | — | ↗ |
| 2021-06-08 | AKKARAJU SRINIVAS | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 6.30 | 110.3K | 17,500 | — | ↗ |
| 2021-03-15 | Olson Eric R | Officer | M-Exempt | D | Stock Option (right to buy) | 3,628 | 1.01 | 3.7K | 90,697 | — | ↗ |
| 2021-02-17 | Springhorn Jeremy P. | Officer | A-Award | A | Stock Option (right to buy) | 94,000 | 11.41 | 1.07M | 94,000 | — | ↗ |
| 2021-02-17 | Simonian Nancy A | Director / Officer | A-Award | A | Stock Option (right to buy) | 304,000 | 11.41 | 3.47M | 304,000 | — | ↗ |
| 2021-02-17 | Roth David | Officer | A-Award | A | Stock Option (right to buy) | 119,000 | 11.41 | 1.36M | 119,000 | — | ↗ |
| 2021-02-17 | Quirk Gerald E | Officer | A-Award | A | Stock Option (right to buy) | 94,000 | 11.41 | 1.07M | 94,000 | — | ↗ |
| 2021-02-17 | Olson Eric R | Officer | A-Award | A | Stock Option (right to buy) | 94,000 | 11.41 | 1.07M | 94,000 | — | ↗ |
| 2021-02-17 | Ferra Joseph J Jr | Officer | A-Award | A | Stock Option (right to buy) | 119,000 | 11.41 | 1.36M | 119,000 | — | ↗ |
| 2021-02-16 | Young Richard A | Director | S-Sale | D | Common Stock | 3,750 | 12.05 | 45.2K | 321,711 | — | ↗ |
| 2021-02-08 | Young Richard A | Director | S-Sale | D | Common Stock | 3,750 | 13.04 | 48.9K | 325,461 | — | ↗ |
| 2020-12-18 | Simonian Nancy A | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 14,168 | 8.51 | 120.6K | 79,165 | — | ↗ |
| 2020-12-08 | AKKARAJU SRINIVAS | Director | A-Award | A | Warrants (right to buy) | 156,250 | 11.00 | 1.72M | 156,250 | — | ↗ |
| 2020-11-17 | Young Richard A | Director | S-Sale | D | Common Stock | 5,357 | 8.75 | 46.9K | 329,211 | — | ↗ |
| 2020-11-16 | Young Richard A | Director | S-Sale | D | Common Stock | 633 | 8.98 | 5.7K | 334,568 | — | ↗ |
| 2020-10-19 | Young Richard A | Director | S-Sale | D | Common Stock | 5,673 | 8.75 | 49.6K | 335,201 | — | ↗ |
| 2020-10-15 | Young Richard A | Director | S-Sale | D | Common Stock | 317 | 8.75 | 2.8K | 340,874 | — | ↗ |
| 2020-09-15 | Young Richard A | Director | S-Sale | D | Common Stock | 5,990 | 10.39 | 62.2K | 341,191 | — | ↗ |
| 2020-09-08 | Eckhardt Sue Gail | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 8.94 | 312.9K | 35,000 | — | ↗ |
| 2020-08-18 | Olson Eric R | Officer | M-Exempt | A | Common Stock | 10,787 | 1.01 | 10.9K | 10,787 | — | ↗ |
| 2020-08-18 | AKKARAJU SRINIVAS | Director | S-Sale | D | Common Stock | 158,583 | 13.10 | 2.08M | 1,274,616 | — | ↗ |
| 2020-08-17 | Young Richard A | Director | S-Sale | D | Common Stock | 5,990 | 12.59 | 75.4K | 347,181 | — | ↗ |
| 2020-08-17 | Olson Eric R | Officer | M-Exempt | D | Stock Option (right to buy) | 4,963 | 1.01 | 5.0K | 105,112 | — | ↗ |
| 2020-08-17 | AKKARAJU SRINIVAS | Director | S-Sale | D | Common Stock | 744 | 13.00 | 9.7K | 1,433,199 | — | ↗ |
| 2020-07-15 | Young Richard A | Director | S-Sale | D | Common Stock | 5,990 | 11.85 | 71.0K | 353,171 | — | ↗ |
| 2020-07-07 | Olson Eric R | Officer | S-Sale | D | Common Stock | 1,753 | 11.72 | 20.5K | 0 | — | ↗ |
| 2020-07-01 | AKKARAJU SRINIVAS | Director | S-Sale | D | Common Stock | 4,627 | 11.01 | 51.0K | 1,433,943 | — | ↗ |
| 2020-06-25 | AKKARAJU SRINIVAS | Director | S-Sale | D | Common Stock | 54,972 | 11.15 | 612.8K | 1,438,570 | — | ↗ |
| 2020-06-24 | AKKARAJU SRINIVAS | Director | S-Sale | D | Common Stock | 48,775 | 11.07 | 539.8K | 1,493,542 | — | ↗ |
| 2020-06-23 | AKKARAJU SRINIVAS | Director | S-Sale | D | Common Stock | 50,953 | 11.11 | 565.9K | 1,542,317 | — | ↗ |
| 2020-06-15 | Young Richard A | Director | S-Sale | D | Common Stock | 5,990 | 8.75 | 52.4K | 359,161 | — | ↗ |
| 2020-06-11 | Young Richard A | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 9.17 | 160.5K | 17,500 | — | ↗ |
| 2020-06-11 | WIRTH PETER | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 9.17 | 160.5K | 17,500 | — | ↗ |
| 2020-06-11 | SHARP PHILLIP A | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 9.17 | 160.5K | 17,500 | — | ↗ |
| 2020-06-11 | Nashat Amir | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 9.17 | 160.5K | 17,500 | — | ↗ |
| 2020-06-11 | Fanucci Marsha | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 9.17 | 160.5K | 17,500 | — | ↗ |
| 2020-06-11 | Alles Mark J | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 9.17 | 160.5K | 17,500 | — | ↗ |
| 2020-06-11 | AKKARAJU SRINIVAS | Director | A-Award | A | Stock Option (right to buy) | 17,500 | 9.17 | 160.5K | 17,500 | — | ↗ |
| 2020-05-15 | Young Richard A | Director | S-Sale | D | Common Stock | 5,990 | 9.22 | 55.2K | 365,151 | — | ↗ |
| 2020-05-13 | Alles Mark J | Director | P-Purchase | A | Common Stock | 10,000 | 8.86 | 88.6K | 10,000 | — | ↗ |
| 2020-04-15 | Young Richard A | Director | S-Sale | D | Common Stock | 23,960 | 8.75 | 209.7K | 371,141 | — | ↗ |
| 2020-02-18 | Olson Eric R | Officer | S-Sale | D | Common Stock | 1,446 | 7.38 | 10.7K | 0 | — | ↗ |
| 2020-02-13 | Springhorn Jeremy P. | Officer | A-Award | A | Stock Option (right to buy) | 94,000 | 7.54 | 708.8K | 94,000 | — | ↗ |
| 2020-02-13 | Simonian Nancy A | Director / Officer | A-Award | A | Stock Option (right to buy) | 294,000 | 7.54 | 2.22M | 294,000 | — | ↗ |
| 2020-02-13 | Roth David | Officer | A-Award | A | Stock Option (right to buy) | 94,000 | 7.54 | 708.8K | 94,000 | — | ↗ |
| 2020-02-13 | Quirk Gerald E | Officer | A-Award | A | Stock Option (right to buy) | 94,000 | 7.54 | 708.8K | 94,000 | — | ↗ |
| 2020-02-13 | Olson Eric R | Officer | A-Award | A | Stock Option (right to buy) | 94,000 | 7.54 | 708.8K | 94,000 | — | ↗ |
| 2020-02-13 | Ferra Joseph J Jr | Officer | A-Award | A | Stock Option (right to buy) | 94,000 | 7.54 | 708.8K | 94,000 | — | ↗ |
| 2019-12-23 | Simonian Nancy A | Director / Officer | M-Exempt | D | Stock Option (right to buy) | 8,210 | 3.04 | 25.0K | 1,018,123 | — | ↗ |
| 2019-12-19 | Alles Mark J | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 6.22 | 217.7K | 35,000 | — | ↗ |
| 2019-11-12 | Springhorn Jeremy P. | Officer | P-Purchase | A | Common Stock | 10,121 | 4.97 | 50.3K | 35,000 | — | ↗ |
| 2019-11-11 | Springhorn Jeremy P. | Officer | P-Purchase | A | Common Stock | 9,879 | 4.99 | 49.3K | 24,879 | — | ↗ |
| 2019-08-16 | Young Richard A | Director | S-Sale | D | Common Stock | 22,700 | 10.00 | 227.0K | 395,101 | — | ↗ |
| 2019-08-15 | Young Richard A | Director | S-Sale | D | Common Stock | 2,300 | 10.00 | 23.0K | 417,801 | — | ↗ |
| 2019-07-17 | ARCH Venture Fund VII, L.P. | 10% Owner | S-Sale | D | Common Stock | 34,521 | 7.70 | 265.7K | 4,242,051 | — | ↗ |
| 2019-07-16 | ARCH Venture Fund VII, L.P. | 10% Owner | S-Sale | D | Common Stock | 25,779 | 7.81 | 201.3K | 4,276,572 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-23.4K
Shares Outstanding
26.83M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Nancy A. Simonian, M.D. Former President & Chief Executive Officer | 635.4K | — | 477.2K | — | 319.0K | 5.2K | 1.44M | 33.21% | ↗ |
| 2 | 2023 | Conley Chee President & Chief Executive Officer | 479.1K | — | 369.5K | — | 192.5K | 690.00 | 1.04M | 35.47% | ↗ |
| 3 | 2023 | Eric R. Olson, Ph.D. Former Chief Scientific Officer | 409.8K | — | 140.7K | — | — | 385.3K | 935.8K | 15.04% | ↗ |
| 4 | 2023 | David A. Roth, M.D Chief Medical Officer | 516.2K | — | 160.8K | — | 197.6K | 2.0K | 876.5K | 18.34% | ↗ |
| 5 | 2023 | Jason Haas Chief Financial Officer | 485.2K | — | 160.8K | — | 185.7K | 1.3K | 833.0K | 19.30% | ↗ |
| 6 | 2022 | Nancy A. Simonian, M.D. President & Chief Executive Officer | 636.6K | — | 1.56M | 974.8K | 316.8K | 2.0K | 3.49M | 72.61% | ↗ |
| 7 | 2022 | Nancy A. Simonian, M.D. Former President & Chief Executive Officer | 636.6K | — | 1.56M | 974.8K | 316.8K | 2.0K | 3.49M | 72.61% | ↗ |
| 8 | 2022 | David A. Roth, M.D. Chief Medical Officer | 497.5K | — | 699.3K | 380.3K | 180.0K | 2.0K | 1.76M | 61.37% | ↗ |
| 9 | 2022 | David A. Roth, M.D Chief Medical Officer | 497.5K | — | 699.3K | 380.3K | 180.0K | 2.0K | 1.76M | 61.37% | ↗ |
| 10 | 2022 | Eric R. Olson, Ph.D. Former Chief Scientific Officer | 487.4K | — | 674.0K | 327.1K | 176.4K | 3.8K | 1.67M | 59.99% | ↗ |
| 11 | 2022 | Eric R. Olson, Ph.D. Chief Scientific Officer | 487.4K | — | 674.0K | 327.1K | 176.4K | 3.8K | 1.67M | 59.99% | ↗ |
| 12 | 2022 | Jason Haas Chief Financial Officer | 465.4K | — | 381.3K | 380.3K | 188.0K | 1.1K | 1.42M | 53.78% | ↗ |
| 13 | 2021 | Nancy A. Simonian, M.D. President & Chief Executive Officer | 615.9K | — | — | 2.41M | 322.9K | 576.00 | 3.35M | 71.98% | ↗ |
| 14 | 2021 | Jason Haas Chief Financial Officer | 91.4K | — | — | 2.36M | 42.5K | 144.00 | 2.50M | 94.63% | ↗ |
| 15 | 2021 | David A. Roth, M.D. Chief Medical Officer | 482.4K | — | — | 944.6K | 185.2K | 576.00 | 1.61M | 58.57% | ↗ |
| 16 | 2021 | Eric R. Olson, Ph.D. Chief Scientific Officer | 481.1K | — | — | 746.2K | 180.7K | 576.00 | 1.41M | 52.98% | ↗ |
| 17 | 2020 | Nancy A. Simonian, M.D. President & Chief Executive Officer | 597.7K | — | — | 1.50M | 429.0K | 360.00 | 2.53M | 59.41% | ↗ |
| 18 | 2020 | David A. Roth, M.D. Chief Medical Officer | 468.3K | — | — | 480.7K | 244.4K | 360.00 | 1.19M | 40.27% | ↗ |
| 19 | 2020 | Eric R. Olson, Ph.D. Chief Scientific Officer | 457.4K | — | — | 480.7K | 238.7K | 360.00 | 1.18M | 40.84% | ↗ |
| 20 | 2019 | Nancy A. Simonian, M.D. President & Chief Executive Officer | 577.7K | — | 1.26M | 1.46M | 319.0K | 360.00 | 3.61M | 75.18% | ↗ |
| 21 | 2019 | David A. Roth, M.D. Chief Medical Officer | 452.1K | — | 583.8K | 383.0K | 189.0K | 360.00 | 1.61M | 60.11% | ↗ |
| 22 | 2019 | Eric R. Olson, Ph.D. Chief Scientific Officer | 443.3K | — | 583.8K | 383.0K | 195.0K | 360.00 | 1.61M | 60.22% | ↗ |
| 23 | 2018 | Nancy A. Simonian, M.D. President & Chief Executive Officer | 560.0K | — | — | 2.16M | 308.0K | 270.00 | 3.03M | 71.36% | ↗ |
| 24 | 2018 | Joseph J. Ferra, Jr. Chief Financial Officer | 323.1K | — | — | 1.86M | 160.0K | 50.2K | 2.39M | 77.73% | ↗ |
| 25 | 2018 | Nancy A. Simonian, M.D. President & Chief Executive Officer Eric R. Olson, Ph.D. Chief Scientific Officer David A. Roth, M.D. Chief Medical Officer | 430.0K | — | — | 569.4K | 189.2K | 270.00 | 1.19M | 47.89% | ↗ |
| 26 | 2018 | David A. Roth, M.D. Chief Medical Officer | 430.0K | — | — | 569.4K | 189.2K | 270.00 | 1.19M | 47.89% | ↗ |
| 27 | 2018 | Nancy A. Simonian, M.D. President & Chief Executive Officer Eric R. Olson, Ph.D. Chief Scientific Officer | 430.0K | — | — | 569.4K | 189.2K | 270.00 | 1.19M | 47.89% | ↗ |
| 28 | 2017 | Nancy A. Simonian, M.D. President & Chief Executive Officer | 525.0K | — | — | 1.39M | 308.0K | 270.00 | 2.22M | 62.52% | ↗ |
| 29 | 2017 | Nancy Simonian, M.D. President & Chief Executive Officer | 525.0K | — | — | 1.39M | 308.0K | 270.00 | 2.22M | 62.52% | ↗ |
| 30 | 2017 | Jeremy P. Springhorn, Ph.D. Chief Business Officer | 53.3K | — | — | 1.75M | — | 34.00 | 1.80M | 97.05% | ↗ |
| 31 | 2017 | David A. Roth, M.D. Chief Medical Officer | 400.0K | — | — | 504.4K | 172.0K | 270.00 | 1.08M | 46.85% | ↗ |
| 32 | 2016 | Nancy Simonian, M.D. President & Chief Executive Officer | 473.3K | — | — | 1.25M | 212.5K | 270.00 | 1.93M | 64.54% | ↗ |
| 33 | 2016 | Gerald E. Quirk, Esq. Chief Legal Officer | 98.3K | — | — | 1.33M | 28.7K | 68.00 | 1.46M | 91.30% | ↗ |
| 34 | 2016 | Kyle D. Kuvalanka Chief Operating Officer | 380.0K | — | — | — | 115.0K | 270.00 | 495.3K | 0.00% | ↗ |
| 35 | 2016 | David A. Roth, M.D. Chief Medical Officer | 380.0K | — | — | — | 115.0K | 270.00 | 495.3K | 0.00% | ↗ |
| 36 | 2015 | Kyle D. Kuvalanka Chief Operating Officer | 106.7K | 122.5K | — | 1.26M | — | 68.00 | 1.49M | 84.63% | ↗ |
| 37 | 2015 | David A. Roth, M.D. Chief Medical Officer | 26.1K | — | — | 1.44M | — | — | 1.46M | 98.22% | ↗ |
| 38 | 2015 | Nancy Simonian, M.D. President & Chief Executive Officer | 425.0K | — | — | 723.2K | — | 270.00 | 1.15M | 62.97% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nathanael S. Gray | Scientific Founder & Member of Scientific Advisory Board | 51.8K | — |
| James E. Bradner | Founder | — | — |
| Matthew Foster | Chief Restructuring Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SYRS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
